PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
November 16, 2020New England Journal of Medicine1,197 citationsOpen Access

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

View Full Paper
DBDeepak L. BhattMSMichael SzarekBPBertram Pitt

Key Points

  • To evaluate the impact of sotagliflozin on cardiovascular and heart failure outcomes in patients with diabetes and chronic kidney disease.
  • Randomized trial comparing sotagliflozin to placebo
  • Participants included those with diabetes and chronic kidney disease, with or without albuminuria
  • Funded by Sanofi and Lexicon Pharmaceuticals; ClinicalTrials.gov number NCT03315143
  • Sotagliflozin lowered the risk of composite events of cardiovascular deaths, heart failure hospitalizations, and urgent heart failure visits compared to placebo.
  • Adverse events were associated with sotagliflozin treatment.

Abstract

In patients with diabetes and chronic kidney disease, with or without albuminuria, sotagliflozin resulted in a lower risk of the composite of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure than placebo but was associated with adverse events. (Funded by Sanofi and Lexicon Pharmaceuticals; SCORED ClinicalTrials.gov number, NCT03315143.).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Bhatt et al. (2020) studied this question.

synapsesocial.com/papers/69d56fa175589c71d767d9f8https://doi.org/10.1056/nejmoa2030186
Ask AI
Helpful
Bookmark
Share
View Full Paper